Tag: Heart Failure
POCUS Measure of JVP Predicts Elevated CVP in Heart Failure
Point-of-care ultrasonography assessment of jugular venous pressure height can predict elevated right atrial pressure
SGLT2 Inhibitor Use May Benefit Patients With HFpEF
SGLT2 inhibitor use may reduce the risk for CV death or hospitalization for heart failure in HF patients with preserved ejection fraction
Aspirin Use Tied to Incident Heart Failure in At-Risk Adults
Aspirin use associated with increased risk for incident heart failure among individuals with or without a history of cardiovascular disease
Genetic Links Between Schizophrenia, CVD Explored
Genetic correlations between schizophrenia and CVD close to zero, but schizophrenia liability may increase heart failure risk
Sacubitril-Valsartan Does Not Cut Risk for Death, Heart Failure After MI
Sacubitril-valsartan not linked to reduced incidence of death from cardiovascular causes or incident heart failure versus ramipril
AHA: Use of Cardiac Rehab Low in Adults With Heart Failure
Rate of enrollment increased after Medicare expansion in 2014, but absolute enrollment rate in cardiac rehabilitation for HF patients still low
AHA: Sacubitril/Valsartan No More Beneficial for Chronic Advanced CHF
No benefit seen versus valsartan for reducing NT-proBNP levels for patients with chronic advanced heart failure and reduced ejection fraction
Cases of Takotsubo Syndrome Up in Middle-Aged, Older Women
Majority of cases (88.3 percent) seen in women, especially those aged 50 years or older; incidence higher in middle-aged men than younger men
SGLT2 Inhibitors May Cut Risk for Heart Failure Hospitalization
SGLT2 inhibitors, compared with GLP-1 RAs, linked to lower risk for heart failure hospitalization in patients with T2DM, with or without CVD
Early Rhythm Control Key in A-Fib and Heart Failure
Reduction seen in composite primary outcomes of CV death, stroke, hospitalization for worsening of heart failure or ACS
